Citicoline vs alpha-GPC: which choline source is better?

If you have shopped for a focus supplement, you have met both of these. Citicoline (also called CDP-choline) and alpha-GPC (alpha-glycerylphosphorylcholine) are the two “premium” choline sources — the ones a serious formula reaches for instead of the cheap choline bitartrate that barely reaches the brain.¹ They do the same core job, they are both well absorbed, and honestly, they are more alike than most head-to-head articles admit. But they are not identical, and one of the differences sits in the safety column — so it is worth understanding what you are actually choosing between.

What they have in common

Both compounds are, at heart, delivery vehicles for choline: the raw material your neurons use to make acetylcholine, the neurotransmitter most tied to memory, learning and focused attention.² Both cross into the brain far better than choline bitartrate, and both have been studied in older adults with cognitive decline with broadly positive results.¹ If your only question is “will this raise brain choline?”, either one clears the bar. The interesting differences are in what else each molecule brings, and in their long-term safety records.

The chemistry: how much choline, and what else

The first difference is simple arithmetic. By weight, alpha-GPC is about 40% choline; citicoline is about 18%.¹ Milligram for milligram, alpha-GPC hands you more raw choline — which is precisely why it is the darling of pre-workout formulas, where a big, fast choline hit is the goal.

But raw choline is not the whole story, because the “other half” of each molecule is different — and that is where citicoline earns its keep.

When citicoline is broken down, it does not just release choline. It also releases cytidine, which the human body converts to uridine — a building block your neurons use to synthesise and repair the phospholipid membranes that make up brain cells.³ A landmark human study confirmed that oral citicoline raises blood levels of both choline and uridine.³ Alpha-GPC’s other half is a plain glycerophosphate carrier with no comparable second act. So citicoline delivers less choline but a genuine second brain nutrient; alpha-GPC delivers more choline and little else. Neither is “wrong” — it depends what you want the supplement to do.

Where alpha-GPC pulls ahead: raw power

Alpha-GPC’s choline density shows up most clearly outside the library. In resistance-trained men, a 600 mg dose taken before training increased peak force production and sharply boosted the post-exercise growth-hormone response versus placebo — an early, small study, but a striking one.⁴ A separate randomised, placebo-controlled crossover found that six days of alpha-GPC improved lower-body isometric force.⁵ The evidence here is smaller-scale than the cognition data, but it points the same way: if your interest is acute physical output — a heavier lift, a more explosive session — alpha-GPC’s big, fast choline delivery has the better case.

Where citicoline pulls ahead: everyday cognition

Citicoline has the stronger record in the population most people buying a nootropic actually belong to: healthy adults. In a randomised, placebo-controlled trial, healthy adult women taking citicoline showed improved attention and reduced errors on a demanding attention task.⁶ It also sits on top of one of the largest clinical-evidence bases of any brain supplement — a review spanning decades of use in cognitive decline and neurological recovery.² Alpha-GPC’s cognitive evidence is real but concentrated in dementia populations: the largest trial gave 261 people with Alzheimer’s 1,200 mg a day for six months and saw meaningful cognitive improvement,⁷ and a 2023 meta-analysis concluded it helps adult-onset cognitive dysfunction.⁸ Strong — but that is medicine for impairment, not evidence in a healthy brain.

The safety question that actually separates them

Here is the part most comparison articles skip, and the one worth reading carefully. In 2021, a cohort study of older adults reported that alpha-GPC use was associated with a higher 10-year risk of stroke, in a dose-dependent way, after adjusting for the usual cardiovascular risk factors — roughly a 46% higher risk in users versus non-users.⁹ Around the same time, a mechanistic study in mice showed that feeding alpha-GPC raised TMAO — a gut-derived molecule linked to atherosclerosis and clotting — and accelerated plaque build-up.¹⁰ The proposed mechanism is intuitive: choline your body does not use can be turned by gut bacteria into TMA, which the liver oxidises to TMAO.

Now the caveats, because they matter and honesty is the whole point of this Journal. The stroke finding is observational — it shows an association, not proof of cause — and much of the alpha-GPC use in that population was at high, pharmaceutical doses (1,200 mg) taken by older people already at elevated vascular risk, which can bias the picture. The atherosclerosis data are from mice. Nobody has shown that a modest nootropic dose meaningfully raises a healthy person’s stroke risk, and the absolute numbers may be small. But it is a real, repeated signal pointing in one direction, and citicoline — which delivers less free choline per dose and carries no comparable epidemiological flag — is simply the more conservative choice for something you intend to take every day for years. Citicoline, for its part, has been given to thousands of people in large clinical trials, including major acute-stroke studies, with a reassuringly clean safety record — even in the trials where it did not change the outcome.¹¹

So which should you take?

For a pre-workout, acute-performance use — occasional, dose-timed, aimed at power — alpha-GPC’s choline density is a fair pick. For daily, long-term cognitive support in an otherwise healthy brain, citicoline is the one we would choose, on two grounds: the second active (uridine) that supports the actual structure of brain cells, and the cleaner long-term safety profile. It is less about one being “better” and more about matching the tool to the job — and to how long you plan to use it.

Where you’ll find it

Both SAP brain formulas are built on citicoline, dosed at 200 mg. In Vyvamind it anchors a fast-acting focus stack; in the stimulant-free Nooceptin it anchors a daily cognitive foundation. If you want the full mechanism — how citicoline reaches the brain and what the uridine half actually does — our deep-dive on citicoline picks up where this comparison leaves off.

References

Peer-reviewed sources for the comparisons and findings above, offered for further reading. Nothing here is medical advice or a claim to treat, cure or prevent any condition.

1. Synoradzki K, Grieb P. Citicoline: a superior form of choline? Nutrients. 2019;11(7):1569.
2. Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63(Suppl 3):S1–S73.
3. Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60(7):989–992.
4. Ziegenfuss T, Landis J, Hofheins J. Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. J Int Soc Sports Nutr. 2008;5(Suppl 1):P15.
5. Bellar D, LeBlanc NR, Campbell B. The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr. 2015;12:42.
6. McGlade E, Locatelli A, Hardy J, et al. Improved attentional performance following citicoline administration in healthy adult women. Food Nutr Sci. 2012;3(6):769–773.
7. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178–193.
8. Sagaro GG, Traini E, Amenta F. Activity of choline alphoscerate on adult-onset cognitive dysfunctions: a systematic review and meta-analysis. J Alzheimers Dis. 2023;92(1):59–70.
9. Lee G, Choi S, Chang J, et al. Association of L-α glycerylphosphorylcholine with subsequent stroke risk after 10 years. JAMA Netw Open. 2021;4(11):e2136008.
10. Wang Z, Hazen J, Jia X, et al. The nutritional supplement L-alpha glycerylphosphorylcholine promotes atherosclerosis. Int J Mol Sci. 2021;22(24):13477.
11. Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349–357.